TLE3 Sustains Luminal Breast Cancer Lineage Fidelity to Suppress Metastasis

Author:

Anstine Lindsey J.1ORCID,Majmudar Parth R.12ORCID,Aponte Amy2ORCID,Singh Salendra3ORCID,Zhao Ran4ORCID,Weber-Bonk Kristen L.1ORCID,Abdul-Karim Fadi W.5ORCID,Valentine Mitchell6ORCID,Seachrist Darcie D.1ORCID,Grennel-Nickelson Katelyn E.2ORCID,Cuellar-Vite Leslie12ORCID,Sizemore Gina M.7ORCID,Sizemore Steven T.7ORCID,Webb Bryan M.123ORCID,Thompson Cheryl L.8ORCID,Keri Ruth A.13ORCID

Affiliation:

1. 1Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

2. 2Department of Pharmacology, Case Western Reserve University, Cleveland, Ohio.

3. 3Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.

4. 4Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

5. 5Department of Pathology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

6. 6Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio.

7. 7Department of Radiation Oncology and the James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.

8. 8Department of Public Health Sciences and the Penn State Cancer Institute, Hershey, Pennsylvania.

Abstract

AbstractBreast cancer subtypes and their phenotypes parallel different stages of the mammary epithelial cell developmental hierarchy. Discovering mechanisms that control lineage identity could provide novel avenues for mitigating disease progression. Here we report that the transcriptional corepressor TLE3 is a guardian of luminal cell fate in breast cancer and operates independently of the estrogen receptor. In luminal breast cancer, TLE3 actively repressed the gene-expression signature associated with highly aggressive basal-like breast cancers (BLBC). Moreover, maintenance of the luminal lineage depended on the appropriate localization of TLE3 to its transcriptional targets, a process mediated by interactions with FOXA1. By repressing genes that drive BLBC phenotypes, including SOX9 and TGFβ2, TLE3 prevented the acquisition of a hybrid epithelial–mesenchymal state and reduced metastatic capacity and aggressive cellular behaviors. These results establish TLE3 as an essential transcriptional repressor that sustains the more differentiated and less metastatic nature of luminal breast cancers. Approaches to induce TLE3 expression could promote the acquisition of less aggressive, more treatable disease states to extend patient survival.Significance:Transcriptional corepressor TLE3 actively suppresses SOX9 and TGFβ transcriptional programs to sustain the luminal lineage identity of breast cancer cells and to inhibit metastatic progression.

Funder

U.S. Department of Defense

National Cancer Institute

National Institute of General Medical Sciences

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Reference74 articles.

1. Molecular portraits of human breast tumours;Perou;Nature,2000

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

3. Oestrogen receptors in breast cancer: basic mechanisms and clinical implications;Williams;Ecancermedicalscience,2013

4. Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies;Marra;NPJ Breast Cancer,2020

5. A new view of the mammary epithelial hierarchy and its implications for breast cancer initiation and metastasis;Anstine;J Cancer Metastasis Treat,2019

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3